Testing an AI chatbot that gives health information for several conditions
Tests the MARVIN AI chatbot for information on HIV, breast cancer and emergencies in children.
Plain-language title generated from the registry record
Registry title: The MARVIN Chatbots to Provide Information for Different Health Conditions
Key facts
- Where
- Montreal, CanadaSee the 2 sites
Where in Canada
- Centre Hospitalier de l'Universite de Montreal (CHUM)Montreal, CanadaTaking people
- McGill University Health Centre (MUHC)Montreal, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Trial code
- NCT05789901
- Record updated
- 6 March 2024
- Original description
This research is a continuation of a usability study with the MARVIN chatbot. The investigators aim to adapt the MARVIN chatbot to open it to other health domains (e.g. breast cancer) and populations (e.g. pharmacists). Therefore, this protocol constitutes a master research protocol that will englobe different research projects with individual chatbots. The investigators adopt an adaptive platform trial design, which will allow flexibility in handling multiple interventions adapted to different populations while retaining the characteristics of a platform trial design allowing early withdrawal of ineffective trial arms based on interim data (implementation outcomes) and introduction of new trial arms.Read full original descriptionShow less
A Master Research Protocol to Adapt and Evaluate an Artificial Intelligence Based Conversational Agent to Provide Information for Different Health Conditions: the MARVIN Chatbots
This research is a continuation of a usability study with the MARVIN chatbot. The investigators aim to adapt the MARVIN chatbot to open it to other health domains (e.g. breast cancer) and populations (e.g. pharmacists). Therefore, this protocol constitutes a master research protocol that will englobe different research projects with individual chatbots. The investigators adopt an adaptive platform trial design, which will allow flexibility in handling multiple interventions adapted to different populations while retaining the characteristics of a platform trial design allowing early withdrawal of ineffective trial arms based on interim data (implementation outcomes) and introduction of new trial arms.
Inclusion: being 14 years or older; being fluent in English and/or French; being able to understand the requirements of study participation and provide informed consent during the duration of the study; having access to a smartphone, tablet, or computer at home/at workplace; having access to an internet connection at home or data plan on their device; accept to use a Facebook Messenger-based Chatbot; accept to use or create a personal Facebook account; accept Facebook's privacy and data security policies.
Exclusion: not meeting the inclusion criteria; any reason, in the opinion of the investigator, which would make the candidate inappropriate for participation in an investigative study involving a chatbot (e.g., cognitive deficit).